CBIO - NASDAQ

Crescent Biopharma, Inc.

CBIO·NASDAQ

$18.45

+8.5%

HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$508.70M

EPS-14.7800

P/E Ratio-1.25

Earnings Date07/30/2026

cbio

Total Debt

Last Annual Value

1.64M

3-Year CAGR

21%

5-Year CAGR

-10%

10-Year CAGR

Adjust for Inflation

Crescent Biopharma, Inc. Competitors Analysis of Total Debt

CBIO · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Crescent Biopharma, Inc. NASDAQ:CBIO	1.64M	26.7%	-3.1%	N/A
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	31.31M	3.2%	N/A	N/A
Anixa Biosciences, Inc. NASDAQ:ANIX	204.00K	5.2%	-4.7%	-26.1%
Cardiff Oncology, Inc. NASDAQ:CRDF	832.00K	-27.1%	-23.2%	-25.8%
Greenwich LifeSciences, Inc. NASDAQ:GLSI	0.00	N/A	N/A	N/A
PepGen Inc. NASDAQ:PEPG	17.00M	-5.4%	N/A	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	2.89M	-68.8%	-34.2%	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	288.02M	33.8%	50.0%	80.1%
Sangamo Therapeutics, Inc. NASDAQ:SGMO	26.80M	-11.1%	-11.0%	21.1%
C4 Therapeutics, Inc. NASDAQ:CCCC	59.98M	-5.5%	6.9%	N/A
Heron Therapeutics, Inc. NASDAQ:HRTX	140.64M	-7.8%	-2.5%	10.3%

Crescent Biopharma, Inc. Fair Value Envelope

CBIO · NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.45, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

HIDDEN

Intrinsic Value

Current Price: $18.45

Related Guides

Blog Categories

Continue your CBIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.